Mercer Global Advisors
AVBP icon

Mercer Global Advisors’s ArriVent BioPharma AVBP Stock Holding History

Mercer Global Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.3K Buy
+2,454
New +$72.4K ﹤0.01% 3952

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mercer Global Advisors's AVBP Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in ArriVent BioPharma (AVBP) in Q2 2026: 2,454 shares worth $85.3K. The stake represents ﹤0.01% of the portfolio and ranks #3952 among its holdings.

141 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Mercer Global Advisors held 2,454 shares of ArriVent BioPharma worth $85.3K as of Q2 2026.
  • ArriVent BioPharma was a new Mercer Global Advisors position in Q2 2026.
  • ArriVent BioPharma made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3952 holding.
  • 141 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.